[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wen-hong Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100513432",false,"NCT05965388","Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy","Inclusion Criteria:\n\n* CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months;\n* Age between 18-80 years, gender is not limited；\n* Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon \\[IFN\\] monotherapy, a potent nucleos(t)ide analogue \\[NA\\] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy;\n* Patient who reads and signs informed consent.\n\nExclusion Criteria:\n\n* Patients with malignancies other than hepatocellular carcinoma.","ALL","18 Years","80 Years",{"count":18,"type":19},5000,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B.\n\nParticipants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.",[23,24],"HBV","HCC","NOT_YET_RECRUITING","2023-07-20",{"date":28,"type":29},"2023-07-28","ACTUAL",{"date":31,"type":19},"2023-12-01",{"date":33,"type":19},"2029-02-01",{"name":35,"class":36},"Wen-hong Zhang","OTHER",10,""]